ONC
BeiGene, Ltd.
NASDAQ: ONC · HEALTHCARE · BIOTECHNOLOGY
$295.27
+1.54% today
Updated 2026-04-30
Market cap
$33.18B
P/E ratio
120.52
P/S ratio
6.21x
EPS (TTM)
$2.48
Dividend yield
—
52W range
$218 – $385
Volume
0.2M
BeiGene, Ltd. (ONC) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+59.5%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-100.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-5.2%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-10.0%
2026-02-26
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-26 | $0.58 | -62.1% | $352.23 | $316.99 | -10.0% |
| 2025-11-06 | $2.65 | +231.2% | $321.39 | $319.97 | -0.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $0.79 | $0.00 | -100.0% | — | — |
| 2025-12-31 | $1.53 | $0.58 | -62.1% | $1.50B | +32.8% |
| 2025-09-30 | $0.80 | $2.65 | +231.2% | $1.41B | +41.0% |
| 2025-06-30 | $0.21 | $0.91 | +333.3% | $1.32B | +41.6% |
| 2025-03-31 | $-0.43 | $0.01 | +102.3% | $1.12B | +48.6% |
| 2024-12-31 | $-1.01 | $-1.43 | -41.6% | $1.13B | +77.8% |
| 2024-09-30 | $-1.04 | $-0.09 | +91.3% | $1.00B | +28.2% |
| 2024-06-30 | $-2.19 | $-1.15 | +47.5% | $929.17M | — |
| 2024-03-31 | $-2.92 | $-2.41 | +17.5% | $751.65M | — |
| 2023-12-31 | $-3.54 | $-3.53 | +0.3% | $634.41M | — |
| 2023-09-30 | $2.01 | $2.01 | +0.0% | $781.31M | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $3.80 | $6.1B | +14.2% | 12 | high |
| 2027 (E) | $5.20 | $7.4B | +21.3% | 12 | high |
| 2028 (E) | $6.80 | $9.1B | +22.3% | 12 | medium |
| 2029 (E) | $8.50 | $11.1B | +22.6% | 12 | medium |
| 2030 (E) | $10.50 | $13.6B | +22.5% | 12 | medium |
Frequently asked questions
Has BeiGene, Ltd. beaten earnings estimates?
BeiGene, Ltd. has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +59.5% over the last 4 quarters.
How does ONC stock react to earnings?
ONC stock has moved an average of -5.2% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is the expected EPS for ONC in 2026?
Analysts expect BeiGene, Ltd. to report EPS of $3.80 for fiscal year 2026, on revenue of $6.1B, based on estimates from 12 analysts.